Published in Cancer Immunol Immunother on January 01, 1991
Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med (1972) 24.43
Cytotoxic effects of lymphoid cells in vitro. Adv Immunol (1969) 8.18
Rosette-formation between human lymphocytes and sheep red cells not involving immunoglobulin receptors. Int Arch Allergy Appl Immunol (1970) 5.92
Cytotoxic potential of stimulated human lymphocytes. J Exp Med (1967) 3.89
Quantitative studies on phytohaemagglutinin-induced cytotoxicity by human lymphocytes against homologous cells in tissue culture. Immunology (1967) 3.87
Phytohaemagglutinin-induced cytotoxic action of unsensitized immunologically competent cells on allogeneic and xenogeneic tissue culture cells. Nature (1965) 2.69
Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med (1999) 2.48
Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet (1986) 2.38
Haemolytic activity of human blood monocytes. Lysis of human erythrocytes treated with anti-A serum. Clin Exp Immunol (1973) 2.21
Cytotoxic action of stimulated lymphocytes on allogenic and autologous erythrocytes. Science (1968) 2.17
Androgen treatment of abdominally obese men. Obes Res (1993) 1.99
Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res (1993) 1.95
Lysis of antibody-treated human erythrocytes by human leukocytes and macrophages in tissue culture. Int Arch Allergy Appl Immunol (1972) 1.77
The in vitro cytotoxicity of human lymphocytes: the effect of metabolic inhibitors. Exp Cell Res (1967) 1.72
Do we need a gender-specific total knee replacement? A randomised controlled trial comparing a high-flex and a gender-specific posterior design. J Bone Joint Surg Br (2012) 1.71
Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry (1978) 1.68
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol (2000) 1.66
Immune deficiency in family members of patients with Hodgkin's disease. Cancer (1990) 1.61
The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord (1992) 1.61
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia (2004) 1.60
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol (1997) 1.57
Impaired phytohaemagglutinin-induced cytotoxicity in vitro of lymphocytes from patients with Hodgkin's disease or chronic lymphatic leukaemia. Clin Exp Immunol (1967) 1.57
The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism (1992) 1.56
A glucocorticoid receptor gene marker is associated with abdominal obesity, leptin, and dysregulation of the hypothalamic-pituitary-adrenal axis. Obes Res (2000) 1.52
Antibodies against endothelial cells and cardiolipin in young patients with peripheral atherosclerotic disease. J Intern Med (1995) 1.51
Variation of flavonoid patterns in Hordeum spontaneum and H. agriocrithon. Hereditas (1975) 1.49
Monoclonal lymphocyte population in human plasma cell myeloma. Clin Exp Immunol (1974) 1.49
Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. Eur J Haematol (1989) 1.48
Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb (1992) 1.46
Characterization of the expanded T-cell populations in patients with Wegener's granulomatosis. J Intern Med (2006) 1.46
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol (1996) 1.45
Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke (2000) 1.43
Lymphocyte subpopulations in sarcoidosis. Clin Exp Immunol (1974) 1.43
In vitro cytotoxic effects of lymphoid cells from rats with experimental autoimmune nephrosis. Clin Exp Immunol (1966) 1.41
Proteinuria and renal function in relation to renal morphology. A clinicopathological study of IgA nephropathy at the time of kidney biopsy. Clin Nephrol (1992) 1.41
LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol (2001) 1.39
Inversion of chromosome 14 marks human T-cell chronic lymphocytic leukaemia. Nature (1984) 1.39
Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol (1995) 1.32
Cytotoxicity of lymphocytes and its suppression. Antibiot Chemother (1969) 1.32
A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun (2002) 1.32
In vitro activation of human T and B lymphocytes by pokeweed mitogen. Clin Exp Immunol (1975) 1.31
Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab (2001) 1.30
Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J Virol (1992) 1.30
Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer (1995) 1.29
A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother (1985) 1.29
In vitro studies of lymphocytes from patients with plasma cell myeloma. II. Characterization by cell surface markers. Clin Exp Immunol (1973) 1.26
Activation of human peripheral blood lymphocytes by concanavalin A dependence of monocytes. Clin Exp Immunol (1975) 1.26
Inhibition of cytotoxic lymphocytes by anti-lymphocytic serum. Transplant Proc (1969) 1.24
In vitro studies of lymphocytes from patients with plasma cell myeloma. I. Stimulation by mitogens and cytotoxic activities. Clin Exp Immunol (1973) 1.21
Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest (2003) 1.20
Acetylcholine receptor antibody in myasthenia gravis: purification and characterization. Scand J Immunol (1978) 1.19
Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1987) 1.18
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Cancer (1976) 1.17
Fast-track surgery for bilateral total knee replacement. J Bone Joint Surg Br (2011) 1.17
Anti-idiotypic monoclonal antibody to a T-cell chronic lymphatic leukemia. Characterization of the antibody, in vitro effector functions and results of therapy. Cancer Immunol Immunother (1989) 1.17
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
The in vitro cytotoxicity of human lymphocytes; comparison with other cells. Exp Cell Res (1967) 1.14
Receptors for Helix pomatia A haemagglutinin on leukaemic lymphocytes from patients with chronic lymphocytic leukaemia (CLL). Clin Exp Immunol (1976) 1.14
Incorporation of 125 I-labelled fibrinogen into coronary arterial thrombi in acute myocardial infarction in man. Lancet (1973) 1.13
Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease. A prospective randomized trial. Ann Oncol (1995) 1.12
Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab (2000) 1.11
The cytotoxic activity of lymphocytes from human lymph in vitro. Clin Exp Immunol (1974) 1.11
Anti-idiotypic antibodies against the receptor antibodies in myasthenia gravis. Scand J Immunol (1981) 1.10
T and CR+ lymphocyte profile in leprosy and the effect of treatment. Infect Immun (1976) 1.10
Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Hum Reprod (2009) 1.10
Physiological variation of blood lymphocyte reactivity: T-cell subsets, immunoglobulin production, and mixed-lymphocyte reactivity. Clin Immunol Immunopathol (1983) 1.10
Immunoglobulins in myasthenia gravis: effect of human lymph IgG 3 and F (ab')2 fragments on a cholinergic receptor preparation from Torpedo marmorata. Eur J Clin Invest (1977) 1.10
Interferon therapy in myelomatosis. Lancet (1979) 1.10
Lymphocyte subpopulations in chronic lymphocytic leukemia. Characterization by cell surface markers, cytotoxic activity, and mitogenic stimulation. Scand J Immunol (1974) 1.09
Insulin resistance in patients with cancer. Cancer Res (1978) 1.08
Food-induced cortisol secretion in relation to anthropometric, metabolic and haemodynamic variables in men. Int J Obes Relat Metab Disord (2000) 1.07
Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol (2001) 1.07
Variations of blood lymphocytes during work studied by cell surface markers, DNA synthesis and cytotoxicity. Clin Exp Immunol (1976) 1.07
Differential cytotoxicity of activated lymphocytes on allogeneic and xenogeneic target cells. I. Activation by tuberculin and by Staphylococcus filtrate. Cell Immunol (1973) 1.06
IgG on human blood lymphocytes studied by immunofluorescence. Scand J Immunol (1978) 1.06
Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol (1991) 1.05
Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol (1996) 1.05
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J (2001) 1.05
Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci (1976) 1.04
Antibody-induced hemolytic activity of human blood monocytes. Scand J Immunol (1974) 1.03
Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1997) 1.03
A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J Nutr (1991) 1.03
Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol (1990) 1.03